심부전에 대한 생맥산 탕제와 양약 병용치료의 효과: 체계적 문헌 고찰과 메타분석
The Effect of Combination Therapy of Saengmaek-san Decoction and Western Medicine on Heart Failure: A Systemic Review and Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study was conducted to evaluate the effectiveness of the combination therapy of Saengmaek-san decoction and Western medicine on heart failure. Methods: A search was conducted on June 22, 2024 using keywords such as “heart failure”, “saengmaeksan”, and “shengmaisan”. A meta-analysis was conducted according to the outcome measurements such as the total effective rate (TER), serum B-type natriuretic peptide (BNP), echocardiography results (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), stroke volume (SV)), and six-minute walk test (6MWT). Data analysis was performed using the RevMan 5.4.1 software, and Cochrane’s risk of bias (ROB) was used to assess the quality of the papers. Results: A total of eight randomized control trials were selected. The treatment group combining Saengmaek-san and Western medicine showed significant improvement effects in terms of TER, BNP, LVEF, LVESD, LVEDD, SV, and 6MWT compared to the control group using Western medicine alone [TER] RR=1.23, 95% CI: 1.13–1.34, p<0.00001; [BNP] MD= -206.14, 95% CI : -257.49–-154.79, p<0.00001; [LVEF] MD=6.40, 95% CI : 5.54–7.27, p<0.00001; [LVEDD] MD=-6.55, 95% CI : -7.24–-5.85, p<0.00001; [LVESD] MD=-3.07, 95% CI: -3.92–-2.22, p<0.00001; [SV] MD=7.12, 95% CI : 5.73–8.50, p<0.00001; [6MWT] MD=43.69, 95% CI : 31.55–55.84, p<0.00001. Conclusion: This study suggests that the combination therapy of Saengmaek-san decoction and Western medicine is effective in treating heart failure. However, these findings should be interpreted cautiously due to the unknown or high risk of bias in the included trials.
Abstract
Objectives: This study was conducted to evaluate the effectiveness of the combination therapy of Saengmaek-san decoction and Western medicine on heart failure. Methods: A search was conducted on June 22, 2024 using keywords such as “heart failure”, “saengmaeksan”, and “shengmaisan”. A meta-analysis was conducted according to the outcome measurements such as the total effective rate (TER), serum B-type natriuretic peptide (BNP), echocardiography results (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), stroke volume (SV)), and six-minute walk test (6MWT). Data analysis was performed using the RevMan 5.4.1 software, and Cochrane’s risk of bias (ROB) was used to assess the quality of the papers. Results: A total of eight randomized control trials were selected. The treatment group combining Saengmaek-san and Western medicine showed significant improvement effects in terms of TER, BNP, LVEF, LVESD, LVEDD, SV, and 6MWT compared to the control group using Western medicine alone [TER] RR=1.23, 95% CI: 1.13–1.34, p<0.00001; [BNP] MD= -206.14, 95% CI : -257.49–-154.79, p<0.00001; [LVEF] MD=6.40, 95% CI : 5.54–7.27, p<0.00001; [LVEDD] MD=-6.55, 95% CI : -7.24–-5.85, p<0.00001; [LVESD] MD=-3.07, 95% CI: -3.92–-2.22, p<0.00001; [SV] MD=7.12, 95% CI : 5.73–8.50, p<0.00001; [6MWT] MD=43.69, 95% CI : 31.55–55.84, p<0.00001. Conclusion: This study suggests that the combination therapy of Saengmaek-san decoction and Western medicine is effective in treating heart failure. However, these findings should be interpreted cautiously due to the unknown or high risk of bias in the included trials.
참고문헌 (31)
- Department of Internal Medicine, Catoholic University of Korea, "Current principles and clinical practice of internal medicine internal medicine", pp.456~473 (2024), Koonja
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392(10159), pp.1789~1858 (2018)
- KSHF, "2022 KSHF Guideline for the Management of heart Failure", KSHF, 5~96 (2022)
- Bell SE, "Prevalence, incidence and survival of heart failure : a systematic review", Heart, 108(17), pp.1351~1360 (2022)
- Tsai MY, "Prescription Pattern of Chinese Herbal Products for Heart Failure in Taiwan : A Population-Based Study", Int J Cardiol, 228, pp.90~96 (2017)
- Wang A, "Mechanisms and Efficacy of Traditional Chinese Medicine in Heart failure", Front Pharmacol, 13, pp.810587~ (2022)
- Kim DC, "Bangjehak", pp.283~284 (2007), YoungRimsa
- Kang SS, "Bareun-Presciption of Korean medicine", pp.92~93 (1996), Daxingwenhuashe
- Wang S, "Shengmai Yin formula exerts cardioprotective effects on rats with chronic heart failure via regulating Linoleic Acid metabolism", Prostaglandins Other Lipid Mediat, 158, pp.106608~ (2022)
- Kim SY, "NECA’s Guidance for Undertaking Systematic Reviews and Meta-analyses for Intervention", National Evidence-based Health care Collaborating Agency, 1~287 (2011)
- Lee JY, "Meta-anallysis", J Korean Endocrinolog, 23(6), pp.361~378 (2008)
- Ye L, "Clinical Study on Modified Shengmai Yin Combined with Western Medicine for Chronic Heart Failure with Qi and Yin Deficiency Syndrome", New Chinese Medicine, 56(10), pp.35~39 (2024)
- 劉坤, "生脉散加味方对充血性心力衰竭患者神经内分泌系统及心功能的影响", 現代中西醫結合雜志, 07, pp.933~936 (2022)
- 楊燕冰, "黄芪生脉散加减治疗慢性心力衰竭(气阴两虚型)临床研究", 四川中醫, 05, pp.92~94 (2022)
- 鄭琪超, "曲美他嗪联合生脉散治疗气阴两虚型慢性心衰患者疗效分析", 海峽藥學, 10, pp.206~207 (2017)
- 張春輝, "黄芪生脉饮联合小剂量多巴胺治疗老年性慢性心力衰竭34例临床观察", 中醫藥導報, 12, pp.51~53 (2015)
- 劉毅, "生脉散辅助治疗慢性充血性心力衰竭临床观察", 長春中醫藥大學學報, 02, pp.277~278 (2013)
- 李越華, "生脉散加味治疗慢性充血性心衰(气阴两虚证)临床研究", 中國中醫急癥, 01, pp.25~26 (2011)
- 闞佑騫, "中西医结合治疗慢性心力衰竭39例疗效观察", 新中醫, 08, pp.19~20 (2007)
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, "ATS statement : guidelines for the six-minute walk test", Am J Respir Crit Care Med, 166(1), pp.111~117 (2002)
- Bilbao A, "The Minnesota living with heart failure questionnaire : comparison of different factor structures", Health Qual Life Outcomes, 14, pp.23~ (2016)
- Department of Internal Medicine, National University of Oriental Medicine, "Asakura Internal Medicine", pp.45~48 (2020), Woori Medicine publication
- Zhou Q, "Shengmai(a traditional Chinese herbal medicine)for heart failure(Review)", Cochrane Database Syst Rev, 4, pp.CD005052~ (2014)
- Yoo BS, "Pharmacological Treatment of Heart Failure", Korean J Med, 81(6), pp.716~719 (2022)
- 涂明玉, "中西医对射血分数保留心力衰竭研究简况", 實用中醫內科雜志, 09, pp.172~175 (2014)
- Association of Korean Medicine Professors for Cardiovascular and Neurological Medicine, "Cardiovascular and Neurological Medicine in Korean MedicineⅠ", pp.131~157 (2016), Woori Medicine publication
- Kim IR, "Bonchohak", pp.573~684 (2004), Yeongnimsa
- Hou Y, "Mechanism of new optimized Sheng-Mai-San Formula to regulate cardiomyocyte apoptosis through NMDAR pathway", Heliyon, 9(6), pp.e16631~ (2023)
- Wu Y, "Signature network-based survey of the effects of a traditional Chinese medicine on heart failure", J Ethnopharmacol, 283, pp.114750~ (2022)
- Zhang K, "Cardioprotection of Sheng Mai Yin a classic formula on adriamycin induced myocardial injury in Wistar rats", Phytomedicine, 38, pp.1~11 (2018)
- Yoo BS, "Biomarkers in Heart Failure : Focus on B-type Natriuretic Peptide", Korean J Med, 82(6), pp.647~650 (2012)